docfrench biotech and pharma companies
download 
Report Transcription
french biotech and pharma companies
FRENCH BIOTECH AND PHARMA COMPANIES BIO EUROPE 2O13 CONVENTION 4-6 NOVEMBER - VIENNA contents INSTITUTIONAL PARTNERS ATLANPOLE BIOTHERAPIES. .............................................................................................................................................................................6 MEDICEN PARIS REGION........................................................................................................................................................................................6 global care.........................................................................................................................................................................................................................7 GENOPOLE..................................................................................................................................................................................................................................8 COMPANIES AFFILOGIC................................................................................................................................................................................................................................ 10 ALIZE PHARMA. ................................................................................................................................................................................................................ 10 ALSACE INTERNATIONAL. ................................................................................................................................................................................. 11 AMYLGEN.................................................................................................................................................................................................................................. 11 Ariana Pharmaceuticals........................................................................................................................................................................ 12 ATLANPOLE BIOTHERAPIES. ......................................................................................................................................................................... 12 ATLANTIC BONE SCREEN.................................................................................................................................................................................. 13 BIOALTERNATIVES....................................................................................................................................................................................................... 13 BIOMEDICAL TISSUES............................................................................................................................................................................................. 14 CARLINA Technologies................................................................................................................................................................................. 14 Cellvax sas. ...................................................................................................................................................................................................................... 15 Ciloa sas................................................................................................................................................................................................................................ 15 CiToxLAB sas.................................................................................................................................................................................................................... 16 Cytune Pharma.......................................................................................................................................................................................................... 16 DRUGABILIS.......................................................................................................................................................................................................................... 17 EUKARYS................................................................................................................................................................................................................................... 17 GENBIOTECH ...................................................................................................................................................................................................................... 18 GENOPOLE.............................................................................................................................................................................................................................. 18 icm..................................................................................................................................................................................................................................................... 19 ICTA................................................................................................................................................................................................................................................... 19 In-Cell-Art....................................................................................................................................................................................................................... 20 2 contents Iris Pharma....................................................................................................................................................................................................................... 20 Iris Pharma....................................................................................................................................................................................................................... 21 l2d services sarl. ................................................................................................................................................................................................ 21 MedinCell........................................................................................................................................................................................................................... 22 Metabolys sas. ............................................................................................................................................................................................................ 22 METABRAIN RESEARCH....................................................................................................................................................................................... 23 MYELOMAX.............................................................................................................................................................................................................................. 23 OTR3................................................................................................................................................................................................................................................. 24 OXELTIS........................................................................................................................................................................................................................................ 24 PELVIPHARM sas.......................................................................................................................................................................................................... 25 PORSOLT sas...................................................................................................................................................................................................................... 25 POXEL sa. ................................................................................................................................................................................................................................. 26 Prestwick Chemical sas.......................................................................................................................................................................... 26 PUP PHARMA sas........................................................................................................................................................................................................ 27 PX’Therapeutics...................................................................................................................................................................................................... 27 QUINTEN.................................................................................................................................................................................................................................... 28 SKULDTECH.......................................................................................................................................................................................................................... 28 SYNCROSOME..................................................................................................................................................................................................................... 29 TEXCELL..................................................................................................................................................................................................................................... 29 Trophos................................................................................................................................................................................................................................... 30 VFP Therapies............................................................................................................................................................................................................... 30 3 notes .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. 4 INSTITUTIONAL PARTNERS 5 ATLANPOLE BIOTHERAPIES CONTACT: Gregory BAUER bauer@atlanpole.fr 95, route de Gachet Château de la Chantrerie 44307 NANTES Cedex 3 Tel: +33 (0)2 40 25 27 20 www.atlanpolebiotherapies.fr ATLANPOLE BIOTHERAPIES gives you access to extended skills, from biodiagnostics to biomedicine in 3 major areas: immunobiotherapies, radiopharmaceuticals and regenerative medicine. For pharmaceutical companies looking for high level partners devoted to healthcare and biotech, ATLANPOLE BIOTHERAPIES is a cluster that draws together a community of innovative companies, fundamental & clinical research organizations and higher education institutions, all located in Western France. Date of creation: 2005 MEDICEN PARIS REGION SECTOR: R&D Services/Biotechnologies CONTACT: Francois CHEVILLARD medicen@medicen.org 3-5, impasse Reille 75014 PARIS Tel: +33 (0)1 79 68 10 86 www.medicen.org MEDICEN PARIS REGION, excellence at the heart of Europe MEDICEN PARIS REGION is your best gateway to access European biotechnologies and markets. Our mission is to maintain and reinforce the Paris Region as Europe’s leading industrial center for diagnostic innovation and health technologies. 3 R&D themes: 1) Translational medicine; 2) Biological tools for industrial use, biotherapeutic products; 3) Digital biology. 3 consolidated disease areas and 2 arising areas: 1) Cancer 2) Neurology 3) Infectiology 4) Cardiometabolism 5) Rare diseases. Date of creation: 2005 6 RUEP CEA ANR-11-CNRT-04 G LC M OA AL BP AN R-11-CNRT-02 GLOBAL CARE TITRE Lieu Date The Global Partnership Research Initiative CONTACT xxx xxx@xxx Tél. B U L L E T I N PROGRAMME of the Carnot Human Health Institutes D ’ I N S C R I P T I O N CONTACT: x x www.x GLOBAL CARE is an outstanding consortium of 5 French expertise centers (honored by the Carnot institute label) research that covers 4 therapeutic fields of major interest in human health: oncology, ophthalmology, infectious diseases and neurology. Supported by our past experience in partnership research and in property management and by the fame of its members, GLOBAL CARE targets the international health market on emerging imaging technologies, innovative diagnostic tools and therapeutic advances. GLOBAL CARE offers behind a joint counter enlarged opportunities to our industrial and research partners worldwide. Bringing greater visibility to our R&D offers, GLOBAL CARE aims at mobilizing multi-disciplinary expertises in response to enterprise needs. More detailed informations on the GLOBAL CARE consortium members below: Pasteur MI (Maladies Infectieuses) The “Pasteur Maladies Infectieuses” (“Pasteur Infectious Diseases”) Carnot institute includes five specialized departments of the “Institut Pasteur” (Virology, Microbiology, Parasitology & Mycology, Infection & Epidemiology, Cell Biology & Infection) that, together with four technological platforms, are dedicated to research on infectious diseases. It brings together basic and applied research activities involving numerous research partnerships with SMEs and large pharmaceutical and diagnostic companies. The goal of research performed at the “Pasteur MI” Carnot institute is to understand basic mechanisms of host cells / pathogen interaction, to develop tools to diagnose known or emerging pathologies, and to perform the clinical validation of vaccines and therapeutic treatments. These works aim at providing an answer to today’s society expectations in public health problems, whether in developed countries (in particular AIDS, antibiotic resistance) or in developing countries (diseases of parasitic origin). « Seeing & Hearing Institute » Built in the heart of Paris, the «Seeing and Hearing» Carnot Institute is one of the most important research center in Europe on eye and audition diseases. Conceived as a place of gathering and exchanges, it brings together the three major actors of the fight against visual and auditive impairments: researchers, clinicians and industrial partners. This proximity enables the sharing of ideas, skills and platforms, the emergence of new questions and facilitates the delicate process of translating fundamental discoveries into new treatments. Our research and development activities are focused onto retinal neuroprotection, sensory readaptation, innovation in clinical investigation (imaging, diagnosis, surgery) and new solutions for the visually impaired people (smart-home, smart-city, accessible services). The Institute’s goal is to discover, test and develop treatments and technological innovations of tomorrow in order to prevent or limit visual and auditive impairment and to improve the autonomy and the quality of life of patients. ICM is a private, not-for-profit, Translational Neuroscience Institute based in Paris, France an rooted in Pitie-Salpetriere, the largest French Neurology Hospital. ICM aggregates more than 500 researchers, a clinical research facility, numerous technological platforms and a start-up incubator within the same building. Main research fields include Parkinson’s disease, Alzheimer, Huntington, ALS, epilepsy, Multiple Sclerosis and Neurooncology, with a total of +50 clinical trials ongoing. It is also the national reference center for 13 rare neurological diseases. THE CURIE INSTITUTE is a leading comprehensive Cancer Center in Paris, France, founded by Marie Curie in 1909. Our Technology Transfer&Licensing Department” is looking for industrial partners to develop patended innovation (120 families), to enter into preclinical R&D collaboration (drug discovery…) as well as into early-stage clinical collaborations. 7 GENOPOLE SECTOR: • Other: (developpement agency, association, institution, cluster) THERAPEuTIC AREA: • Cardiovasculr • Diseases of the blood, immune disorders • Disease of ear or eye MEMBER OF COMPETITIVE CLuSTER: Medicen CONTACTS: Patricia RIGOU patricia.rigou@genopole.fr 5, rue Henri Desbruères Genopole Campus 1 91030 Evry Cedex Tel: +33 (0)1 60 87 83 00 genopole.fr Frédéric ZAMPATTI frederic.zampatti@genopole.fr GENOPOLE® is the leading French Science Park dedicated to life sciences. Located in the Paris Region Biocluster, 30 km south of the city, we offer business support and incubation to biotech companies in biopharmaceuticals, diagnostics, medical devices, scientific instrumentation, agrifood, environment and chemistry. We also assist French and foreign companies in establishing their R&D, commercial or industrial operations in the southern Paris Biocluster to benefit from world-class hospitals, higher University education, biotech and pharma companies. • 71 companies • 21 academic research labs • 2 148 staff Date of creation: 1998 8 Biotechs companies Date of creation: 1996 Nombre d’employés: 43 Date of creation: 1996 Nombre d’employés: 43 9 AFFILOGIC SECTOR: • Therapeutics • Diagnostic THERAPEuTIC AREA: • Digestive system • Disease of ear or eye • Disease of nervous system CONTACT: Nadège PREL Business Development Manager nadege@affilogic.com 2, rue de la Houssinière 44000 NANTES Tel: +33 (0)2 51 12 56 95 www.affilogic.com AFFILOGIC is a biotech company developing a new class of affinity ligands, Nanofitins®, which are able to selectively bind many targets and have proven excellent tools for: • Targeting (immunolocalization, in vivo neutralization): Therapeutic applications • Capture (affinity chromatography, protein removal): Bioprocessing applications • Detection (immunoassays, Western Blot): Diagnostic applications. Date of creation: 2010 ALIZE PHARMA SECTOR: Therapeutics THERAPEuTIC AREA: • Endocrine&metabolic diseases • Cancer, Oncology CONTACT: Valérie WESLEY vwesley@alz-pharma.com 15, chemin du Saquin Espace europeen - BAT G 69130 ECULLY Tel: +33 (0)4 72 18 94 28 www.alz-pharma.com ALIZÉ PHARMA is a group of companies specialized in the development of innovative biopharmaceutical drugs for the treatment of metabolic diseases and rare diseases. ALIZÉ PHARMA SAS is dedicated to AZP-531, a peptide derived from unacylated ghrelin, currently in Phase I, to be developed in type 2 diabetes, the Prader Willi syndrome and some ischemia-related cardiovascular conditions. ALIZÉ PHARMA II SAS, is focused on ASPAREC®, a new PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia, currently undergoing Phase I clinical development. 10 ALSACE INTERNATIONAL Le Sebastopol 3, Quai Kléber 67000 STRASBOURG Tel: +33 (0)3 88 24 77 68 www.alsace.com International Office ALSACE INTERNATIONAL 40 Wellesley Street Weston, MA 02493 USA Tel: +1 (781) 894 7486 Mob. +1 (617) 306 1541 CONTACTS: Patricia HATESUER Business Development Manager p.hatesuer@alsace-international.eu Andrew CLUTZ Director, Business Development ALSACE INTERNATIONAL is the economic development agency of the Alsace region and an active member of the Alsace BioValley Cluster, a unique environment, rich in business and research opportunities. Alsace International provides free and confidential customized services to companies interested in exploring Alsace as a possible location in Europe to carry out activities including R&D, Service providing, Sales and Marketing, Manufacturing, Regional Headquarters, Clinical trials, collaborative research (public or private collaborations)… Nombre d’employés: 25 AMYLGEN SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system CONTACT: Vanessa VILLARD vanessa.villard@amylgen.com Place Eugene Bataillon CC105 34095 MONTPELLIER Tel: +33 (0)4 67 14 36 86 www.amylgen.com AMYLGEN has developed a unique and proprietary know-how on Alzheimer’s disease rodent models based on central injection of amyloid peptide fragments with validated predictive value. Other models for schizophrenia, dépression, stroke are also available. AMYLGEN’s models and techniques allow fast-scale screening and pre-clinical validation for the pharmaceutical development of new drug candidates at a very early stage of development. Date of creation: 1/10/2009 Nombre d’employés: 6 11 ARIANA PHARMACEuTICALS SECTOR: • Therapeutics • Diagnostic THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Diseases of the blood, immune disorders 28, rue du Docteur Finlay 75015 PARIS Tel: +33 (0)1 44 37 17 00 www.arianapharma.com International Office Ariana Data Intelligence Inc. One Broadway - 14th Floor Cambridge, MA 02142 - USA CONTACT: Mohammad AFSHAR Chairman & CEO info@arianapharma.com ARIANA® accurately identifies the best patient responder sub-groups in clinical trials, and optimizes biomarker/diagnostic signatures using its unique technology. ARIANA applies its proprietary “rules-based” data analytical approach – KEM® - to clinical datasets to identify complex relations that all other approaches miss, thus enabling decision-makers to optimize all possible endpoints simultaneously. ARIANA’s world-class team of experienced, inter-disciplinary scientists includes PhD biologists, computer scientists, biostatisticians, bio-informatics specialists, chemists and clinical experts. ARIANA was founded in 2003 as a spin-off from the Institut Pasteur, and has offices in Paris, France and Cambridge, Mass, USA. Date of creation: 2003 ATLANPOLE BIOTHERAPIES CONTACT: Gregory BAUER bauer@atlanpole.fr 95, route de Gachet Château de la Chantrerie 44307 NANTES Cedex 3 Tel: +33 (0)2 40 25 27 20 www.atlanpolebiotherapies.fr ATLANPOLE BIOTHERAPIES gives you access to extended skills, from biodiagnostics to biomedicine in 3 major areas: immunobiotherapies, radiopharmaceuticals and regenerative medicine. For pharmaceutical companies looking for high level partners devoted to healthcare and biotech, ATLANPOLE BIOTHERAPIES is a cluster that draws together a community of innovative companies, fundamental & clinical research organizations and higher education institutions, all located in Western France. Date of creation: 2005 12 ATLANTIC BONE SCREEN SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cancer, oncology CONTACT: Elisabeth PORCHER elisabeth.porcher@atlantic-bone-screen.com 3, rue Aronnax 44821 SAINT HERBLAIN Cedex Tel: +33 (0)2 40 41 11 25 www.atlantic-bone-screen.com ATLANTIC BONE SCREEN is a French Preclinical CRO providing biological evaluation services in the field of bone and joint diseases and in the field of bone tumors. We provide In vitro assays( bone and joint cells, tumor cells), In vivo assays (Experimental models in mice and rats: osteoporosis, osteoarthritis, rheumatoid arthritis, osteosarcoma, bone metastases from breast and prostate cancer), ex vivo analyses (histology, immunohistochemisty, imagery, ELISA assays). ATLANTIC BONE SCREEN has an affiliated company, ATLANCHIMPHARMA provides custom-made chemical synthesis services Date of creation: october 2005 Nombre d’employés: 10 BIOALTERNATIVES SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Diseases of the blood, immune disorders • Disease of nervous system • Endocrine&metabolic diseases CONTACT: Maxance VANDEVYVERE contact@bioalternatives.com 1bis, rue des Plantes 86160 GENÇAY Tel: +33 (0)5 49 36 11 37 www.bioalternatives.com BIOALTERNATIVES is a private company (Contract Research Organization) specialized in Cellular and Molecular Pharmacology. BIOALTERNATIVES provides services to support the early stages of drug discovery and the claim substantiation of healthcare compounds using up-to-date in vitro solutions. Date of creation: 1996 Nombre d’employés: 43 13 BIOMEDICAL TISSuES SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Skin&subcutaneous tissue CONTACT: Valérie DUMAY vdumay@biometiss.com IRT UN 8, quai Moncousu 44000 NANTES Tel: +33 (0)2 28 08 00 37 www.biometiss.com BIOMEDICAL TISSUES is a Medtech company dedicated to the development of implantable medical devices for regenerative medicine. The company provides his customers with services in the field of implants surface treatment (ISO13485 certified). Besides, Biomedical Tissues develops medical devices, based on a unique technology of synthetic polymer microfibers synthesis, for soft tissues regeneration. Date of creation: 01/10/2010 Nombre d’employés: 4 CARLINA TECHNOLOGIES SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Endocrine&metabolic diseases • Cancer, Oncology CONTACT: Olivier MEYER omeyer@carlinatech.com 22, rue Roger Amsler 49100 ANGERS Tel: +33 (0)2 41 24 92 82 www.carlinatech.com CARLINA TECHNOLOGIES is a biopharmaceutical company specialized in the development of micro- and nano-medicines. The company provides R&D formulation development services to the pharmaceutical, veterinary and biotechnology industries as well as it develops improved versions of first generation drugs for the treatment of cancer and diabetes using innovative encapsulation platforms. Date of creation: 23 juillet 2010 14 CELLVAx SAS SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Diseases of the blood, Immune disorders • Cancer, Oncology CONTACT: Ming WEI ming@cellvax-pharma.com 4, rue Pierre Fontaine 91058 EVRY Tel: +33 (0)1 43 76 32 65 www.cellvax-pharma.com CELLVAX is a French SME which provides complete preclinical innovating drug validation studies both in vitro and in vivo (rodents and non-rodents) allowing to accelerate the drug development process for unmet needs related with severe human diseases, mainly in cancer field. Date of creation: Juin 2001 CILOA SAS SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Diseases of the blood, immune disorders CONTACT: Robert MAMOUN rmamoun@ciloa.fr Bat. 24, cc107 Universite Montpellier 2 Place E. Bataillon 34095 MONTPELLIER Cedex 5 Tel: +33 (0)4 67 14 39 97 www.ciloa.fr CILOA offers custom production of fully native membrane proteins on exosomes, therapeutic mAbs against membrane proteins and collaboration for vaccine development. Ciloa has a full pipeline for mAb development with: 1. fully native membrane antigens (GPCRs, Kinase receptors, Ion channels, Viral Envelope proteins, etc.). 2. Hybridoma dev. with proprietary powerful immunization protocol. 3. Proprietary Human scFv Phage library focused on membrane Antigens. 4. ELISA screening & SPR characterization. Date of creation: Mars 2011 Nombre d’employés: 8 15 CITOxLAB SAS SECTOR: Other: (developpement agency, association, institution, cluster) CRO - Preclinical services B.P. 563 - 27005 EVREUX Cedex Tel: +33 (0)2 32 29 26 26 www.citoxlab.com CONTACT: Stéphane DE FORTESCU stephane.defortescu@fr.citoxlab.com CiToxLAB North America 445, Armand-Frappier Blvd Laval, Quebec H7V 4B3 - CANADA CiToxLAB Hungary Veszprém, Szabadságpuszta 8200, HUNGARY CiToxLAB Scantox Hestehavevej 36A, Ejby DK-4623 Lille Skensved DENMARK CITOXLAB, a leading non-clinical CRO (France, Canada, Denmark and Hungary) offers in vitro and in vivo safety studies. With more than 40 years of experience in safety and general pharmacology, genotoxicology, genomics, DART, immunotoxicology, pathology, dermal, ocular, inhalation, infusion, and carcinogenicity testing, along with ADME and bioanalysis. Our facilities are GLP and AAALAC certified. Date of creation: 1969 Nombre d’employés: 850 CYTuNE PHARMA SECTOR: Therapeutics THERAPEuTIC AREA: • Cancer, Oncology CONTACTS: Didier COQUOZ PharmD, PhD, CDO/C BD&L didier.coquoz@cytune-pharma.com 7, avenue Amédée Ménard 44300 NANTES Mob.: +33 (0)6 66 49 55 94 www.cytunepharma.com David Bechard, PhD, MBA, President, COO david.bechard@cytune-pharma.com CYTUNE develops CYP0150 that uniquely mimics the major MoA of IL-15 even in pathologic conditions. CYP0150 restores a potent but balanced immune response and is a unique opportunity within the successful family of anti-immunosuppressive agents such anti-CTLA4 and anti-PD1. CPY0150 alone and in combination was shown to have promizing efficacy in different animal tumor models and to be superior to IL-2. Moreover, CYTUNE develops a broad portfolio of potent immunocytokines, i.e. monoclonal antibody fused to CYP0150. These ICKs enable to manage the product Life Cycle Management for existing blockbusters and to increase the efficacy of existing or future antibodies. Date of creation: 2007 16 DRuGABILIS SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Diseases of the blood, immune disorders CONTACT: Joel VACUS joel.vacus@drugabilis.com 5, rue Jean Baptiste Clément 92290 CHATENAY MALABRY Tel: +33 (0)1 46 61 28 50 www.drugabilis.com DRUGABILIS is a CRO specialized in pharmaceutical physicochemical characterization and formulation as applied to the early selection of new drug candidates and their formulations. DRUGABILIS management and scientists have an extensive experience of industrial pharmaceutical research support. The company offer includes solubility and stability screenings, salt and polymorphism screenings, formulation design for animal dosing (any route of administration/any animal model/low-soluble compounds...), preformulation studies, phase I formulation strategy set-up. Date of creation: 2004 EuKARYS SECTOR: • Therapeutics • R&D services/biotechnologies CONTACT: Benjamin BERTRAND benjamin@eukarys.com Pépinière « Genopole Entreprises » CAMPUS 3 - 4, rue Pierre Fontaine 91058 EVRY Cedex Mob.: +33 (0)6 24 00 17 53 www.eukarys.com High performance high yield cell-free messenger RNA production systems for research, cell therapies, human vaccines, cell reprogramming. The C3P3® mRNA Production System has three decisive competitive advantages: 1) increased mRNA yields; 2) fully mature mRNA with very high rate of native capping, and poly(A)tail, enhancing protein expression; 3) Easy-to-Use and Quick: One-step process instead of 3 or 4 to a produce completely capped, poly(A)-tailed mRNA. Other advantages: stability, immunogenicity, poly(A)-tails of equal or customized length, non-viral. Date of creation: 210 Nombre d’employés: 3 17 GENBIOTECH SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Diseases of the blood, immune disorders • Skin&subcutaneous tissue CONTACT: mail@genbiotech.com Z.I. les 3 Moulins 280, rue de Goa - B.P. 60053 06901 SOPHIA-ANTIPOLIS Tel: +33 (0)4 92 91 32 23 www.genbiotech.com The creation of GENBIOTECH, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and gynecology worldwide. GENBIOTECH aims to bring together people and resources required for Research and Development and Marketing innovative biotechnological therapies adapted to patients’ needs. Date of creation: 24/10/2012 GENOPOLE SECTOR: Other: (developpement agency, association, institution, cluster) Biocluster THERAPEuTIC AREA: • Cardiovasculr • Diseases of the blood, immune disorders • Disease of ear or eye CONTACTs: Patricia RIGOU patricia.rigou@genopole.fr 5, rue Henri Desbruères Genopole Campus 1 91030 EVRY Cedex Tel: +33 (0)1 60 87 83 00 www.genopole.fr Frédéric ZAMPATTI frederic.zampatti@genopole.fr GENOPOLE® is the leading French Science Park dedicated to life sciences. Located in the Paris Region Biocluster, 30 km south of the city, we offer business support and incubation to biotech companies in biopharmaceuticals, diagnostics, medical devices, scientific instrumentation, agrifood, environment and chemistry. We also assist French and foreign companies in establishing their R&D, commercial or industrial operations in the southern Paris Biocluster to benefit from world-class hospitals, higher University education, biotech and pharma companies. - 71 companies - 21 academic research labs - 2 148 staff Date of creation: 1998 18 ICM SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system • Mental & behavioural disorders • Cancer, oncology CONTACT: Alexis GENIN Directeur des Applications de la Recherche alexis.genin@icm-insitute.org BRAIN & SPINE INSTITUTE (ICM) Hôpital Pitié Salpêtrière 47, boulevard de l’Hôpital 75013 PARIS Tel: +33 (0)1 57 27 40 00 http://research.icm-institute.org/ ICM is a private, not-for-profit, Translational Neuroscience Institute based in Paris, France an rooted in Pitie-Salpetriere, the largest French Neurology Hospital. ICM aggregates more than 500 researchers, a clinical research facility, numerous technological platforms and a start-up incubator within the same building. Main research fields include Parkinson’s disease, Alzheimer, Huntington, ALS, epilepsy, Multiple Sclerosis and Neurooncology, with a total of +50 clinical trials ongoing. It is also the national reference center for 13 rare neurological diseases. Date of creation: 2010 Nombre d’employés: 600 ICTA SECTOR: • Therapeutics • R&D services/biotechnologies • Diagnostic THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Diseases of the blood, immune disorders International Office ICTA GmbH - Lebacher Strasse 4 - D-66113 Saarbrücken ICTA – INTERNATIONAL CLINICAL TRIALS ASSOCIATION 11, rue du Bocage 21121 FONTAINE LES DIJON Tel: +33 (0)3 80 53 40 00 www.icta.fr CONTACT: Olivier HUMBEY olivier.humbey@icta.fr ICTA (INTERNATIONAL CLINICAL TRIALS ASSOCIATION) is an international privately-owned CRO with 30 years of experience in clinical R&D, pharmaco-epidemiology and expanded access programs for APIs, cell therapies, diagnostics and medical devices. ICTA’s international operations in Europe and the USA provide full clinical research or “a la carte” services in traditional and adaptive clinical trials from Early Phase to Late Phase across a broad range of therapeutic areas... Date of creation: 01/05/1984 Nombre d’employés: 350 19 IN-CELL-ART SECTOR: • Therapeutics • Diagnostic • R&D services/biotechnologies THERAPEuTIC AREA: • Infectious and parasistic diseases • Cancer, oncology CONTACT: Sohei FUKUYAMA MBA Business Development & Alliance Management sohei.fukuyama@incellart.com 21, rue de la Noue Bras de Fer 44200 NANTES Tel: +33 (0)2 40 71 67 17 www.incellart.com ICA was founded in 2005 by a research team including a Nobel Prize laureate. ICA is specialized in nanocarriers for macromolecule delivery and it has collaborations with DARPA (US Ministry of Defense), Sanofi Pastuer, Merial and more. In 2012, Deloitte awarded ICA as one of the fastest growing biopharmaceutical firms between 07 and 11 in France. Currently, ICA has 4 core activities based on the delivery system: Vaccine, Gene Therapy , Antibody Discovery and iPSc, Date of creation: 2005 IRIS PHARMA SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Disease of ear or eye CONTACT: Pierre-Paul ELENA info@iris-pharma.com Allée Hector Pintus 06610 LA GAUDE Tel: +33 (0)4 93 59 49 59 www.iris-pharma.com A leading contract research organization (CRO) dedicated to ophthalmology, IRIS PHARMA helps clients around the world navigate every stage of the drug and device development process – including in vivo screening, proof of concept, ocular efficacy, GLP preclinical studies, bioanalysis, clinical trials, and marketing surveys. IRIS PHARMA has partnered with clients to bring more than 40 ocular drugs and medical devices to market in the past 24 years, in addition to offering consulting services to help clients determine the best indication for molecules and products in development. This CRO has expertise in all ophthalmic indications, and supports clients ranging from small startups to large pharmaceutical companies in moving forward products that directly or indirectly affect eye health. Date of creation: 1989 Nombre d’employés: 60 20 KEOSYS SAS SECTOR: • Diagnostic • R&D services/biotechnologies • Other: (developpement agency, association, institution, cluster) Medical Imaging Services for clinical Trials THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Diseases of the blood, immune disorders 1, Impasse Augustin Fresnel 44815 SAINT-HERBLAIN Tel: +33 (0)2 40 92 26 13 www.keosys.com International Office Philadelphie (U.S.A) CONTACT: Lydia BEHLOUL lbe@keosys.com KEOSYS Medical Imaging is a global company specialized in IT applied to Medical Imaging within clinical research and medical diagnosis. KEOSYS offers full medical imaging services for phase II-III-IV drug and device medical imaging clinical trials whatever the imaging modalities and the therapeutic areas. KEOSYS’ expertise relies on its deep knowledge of the medical imaging requirements in clinical study projects and on its expert medical team (radiologists, nuclear medicine physicians, gastroenterologists, cardiologists, neurologists, rheumatologists, dermatologists…). Date of creation: 2001 L2D SERVICES SARL SECTOR: R&D services/biotechnologies CONTACT: J. KEARSEY jkearsey@leadstodevelopment.com leads to development 166, boulevard du Montparnasse 75014 PARIS www.leadstodevelopment.com LEADS TO DEVELOPMENT (L2D) specializes in the early-stage development of therapeutic products. We offer consultancy, regulatory and operational management services to our clients in order to help them bridge the gap between therapeutic lead identification and clinical development. Our clients benefit from our development expertise without having to build additional internal headcount, whilst we ensure that their products are advanced rapidly and cost effectively to clinical proof of concept. We offer a personal service carefully tailored to our customers’ needs that maintains the transparency, flexibility and availability associated with an internal team Date of creation: 2009 Nombre d’employés: 5 21 MEDINCELL SECTOR: Therapeutics THERAPEuTIC AREA: • cCardiovasculr • Digestive system • Diseases of the blood, immune disorders Parc Clément Ader 1, avenue Charles Cros 34830 JACOU Tel: +33 (0)4 67 41 99 74 www.medincell.com International Office MedinCell Corporation 10451 Roselle St, Suite 200 San Diego CA 92121 CONTACT: Sebastien ENAULT sebastien.enault@medincell.eu MEDINCELL’s controlled-release delivery platform offers wide-ranging durations—from several days up to one year—for many small molecules and biologics, and requires no API modification. Current commercial partnerships aim to address delivery hurdles across arthritis, oncology, contraception, diabetes, and our low-cost manufacturing enables partners to target fast-growing emerging markets. Date of creation: 2002 METABOLYS SAS SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system • Endocrine&metabolic diseases • Cancer, oncology CONTACT: Gabriel BAVEREL baverel@metabolys.com Laennec Faculty of Medicine 7-11, rue G. Paradin 69008 LYON Mob.: +33 (0)6 84 85 57 75 www.metabolys.com METABOLYS has a drug discovery line in the diabetes field. Six antidiabetic candidates are protected by 4 patents; one of them is being developed and will be out-licensed. METABOLYS has also a service activity consisting of predicting the safety and efficacy of drug candidates using a metabolic flux analysis approach. Date of creation: 20/11/2008 Nombre d’employés: 6 22 METABRAIN RESEARCH SECTOR: • Therapeutics • Diagnostic • R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Disease of nervous system • Endocrine&metabolic diseases CONTACT: Valerie AUTIER v.autier@metabrainresearch.com 4, avenue du pdt f. Mitterrand 91380 CHILLY MAZARIN Tel: +33 (0)1 69 19 41 50 www.metabrainresearch.com METABRAIN is a diabetes research center (Paris area). Its 30 collaborators operate integrated and disease oriented medicinal chemistry, molecular, cellular and animal pharmacology, gather long term industrial experience in discovery and drug development. Since 2009, METABRAIN is conducting research partnerships with main French Biotechs and Pharmas. It develops drugs and nutraceuticals and associated biomarkers that address several interconnected chronic diseases such as diabetes, obesity, muscle dysfunction and memory troubles, for the elder population which requires alternatives to existing therapies. Date of creation: 10/03/2009 Nombre d’employés: 30 MYELOMAx SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cancer, oncology CONTACT: contact@myelomax.com IRS_UN 8, quai Moncousu 44007 NANTES Tel: +33 (0)2 28 08 00 40 www.myelomax.com MYELOMAX is a french CRO specialized in preclinical evaluation services in the field of multiple myeloma. Our mission is to assist our clients in the evaluation of drug efficacy, mechanism of action, combination with approved drugs, identification of biomarkers using our large and unique collection of Human Multiple Myeloma Cell Lines covering the molecular and functional diversity of Multiple Myeloma. 23 OTR3 SECTOR: Therapeutics THERAPEuTIC AREA: • Cancer,oncology • Skin&subcutaneous tissue CONTACT: Denis BARRITAULT denis.barritault@otr3.com 4, rue Française 75001 PARIS Tel: +33 (0)1 83 62 78 83 www.otr3.com OTR3 is developing products in regenerative medicine from innovative proprietary molecules: the RGTA. RGTA are biodegradable polysaccharides engineered to restore the cellular microenvironment after lesion and favor tissue regeneration without external input of stem cells. Two products are on the market: CACIPLIQ20 and CACICOL20 to treat skin and corneal ulcers. Two developments are in clinical trials to treat mucositis and radiation dermatitis in cancer patients. Marketing authorization is expected within 1 year. OTR3 is looking for licensees and developments partners. Date of creation: July 2000 Nombre d’employés: 13 OxELTIS SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Infectious and parasistic diseases • Cancer, oncology CONTACT: Jean-Marc ALLAIRE contact@oxeltis.com Cap Gamma 1682, rue de la Valsière C.S. 27384 34189 MONTPELLIER Cedex 4 Tel: +33 (0)4 99 23 50 36 www.oxeltis.com OXELTIS is a medicinal chemistry service company delivering integrated solutions for managing and executing medicinal and fine organic chemistry projects in the field of NCE discovery and optimization. OXELTIS is particularly active in the anti-infective and oncology fields. OXELTIS team expertise and background is related to medchem research for the past 10 years. Its expertise in organic chemistry is in heterocycles, macrocycles, sugars, nucleos(t)ides and phosphorus chemistry. OXELTIs is located in Montpellier-France and was founded in 2010 by former management and research team from Idenix Pharmaceuticals Date of creation: September 2010 24 PELVIPHARM SAS SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Disease of nervous system CONTACT: Delphine BEHR-ROUSSEL d.behr.roussel@pelvipharm.com Orsay Parc 86, rue de Paris 91400 ORSAY Tel: +33 (0)1 70 42 93 39 www.pelvipharm.com PELVIPHARM is a CRO delivering preclinical research services across a range of therapeutic areas including urology (BPH, OAB, NDO, SCI, SUI, IC…), sexual (ED, PE, FSD…) and cardiovascular medicine (Hypertension, Atherosclerosis, Metabolic Syndrome, Diabetes,Myocardial Infarction…). PELVIPHARM provides customized outsourcing services to clients according to their outsourcing needs, using both in vivo experimental models and in vitro animal and human tissue-based specific research services based on the most recent exploration methods. Date of creation: 1999 Nombre d’employés: 14 FTE PORSOLT SAS SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Disease of ear or eye CONTACT: Sébastien BRECHE sbreche@porsolt.com Z.A. de Glatigné 53940 LE GENEST SAINT ISLE Tel: +33 (0)2 43 69 36 07 www.porsolt.com PORSOLT is a long-established preclinical CRO with an international reputation for expertise in physiopathological models, customized procedures and tailored solutions for discovering treatments of psychiatric & neurological diseases, acute & chronic pain, inflammation, cardio vascular diseases, and metabolic disorders. PORSOLT also offers services for safety evaluation of drug candidates from screening to pre-Phase 1 regulatory studies (ICH S7), in full GLP compliance. PORSOLT’s safety program includes full assessment of arrhythmogenic risk and abuse/dependence liability. Date of creation: 1984 25 POxEL SA SECTOR: • Therapeutics THERAPEuTIC AREA: • Endocrine&metabolic diseases CONTACT: Pascale MALGOUYRES pascale.malgouyres@poxelphama.com 200, avenue Jean Jaurès 69007 LYON Tel: +33 (0)4 37 37 20 10 www.poxel.com POXEL is a biopharmaceutical company developing innovative first-in-class drugs with a primary focus on Type 2 diabetes. The company develops novel treatments before partnering with pharmaceutical companies. POXEL operates independently as a lean organization with strong in-house drug development and business expertise. Its R&D pipeline consists in innovative programs with new mechanism of action, agents profiled for their activity on glucose metabolism and cardiovascular risk factors, all with an improved safety profile compared to current available therapies. Date of creation: 2009 Nombre d’employés: 13 PRESTwICK CHEMICAL SAS SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Disease of nervous system CONTACT: Paul BIKARD paul.bikard@prestwickchemical.fr 220, boulevard Gonthier d’Andernach STRASBOURG-ILLKIRCH Tel: +33 (0)3 69 20 16 00 www.prestwickchemical.com PRESTWICK CHEMICAL is a drug discovery company that successfully identifies hits for the project’s target and optimizes the hits into clinical candidates. With our premium partners, we have developed the capacity to integrate the whole drug research: Hit identification using smart screening libraries and/or large scale pharmacophore based virtual screening, hit validation, hit to lead expansion, lead optimization and profiling and have unprecedented success towards development. Date of creation: 1999 26 PuP PHARMA SAS SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Digestive system • Disease of nervous system • Injury, poisoning CONTACT: David CHAUVIER dchauvier@puppharma.fr 102, avenue Gaston Roussel 93230 Romainville Tel: +33 (0)9 81 30 80 12 www.puppharma.fr PUP PHARMA’s unique experimental services tailored to our customer’s specific perinatal and paediatric applications, allowed preclinical efficacy and safety drug evaluation in the context of pathological/physiological conditions from prematurity to childhood. Our pharmacological services allow either complying with the mandatory Pediatric Investigation Plan or identifying new indications for yours products in the field of Central Nervous System, Pulmonary or Inflammatory Systems. Date of creation: aout 2010 Px’THERAPEuTICS SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Diseases of the blood, immune disorders CONTACT: Claire UNTEREINER claireuntereiner@px-therapeutics.com Minatec BHT52A 7, parvis Louis Néel 38040 GRENOBLE Tel: +33 (0)4 38 02 36 50 www.px-therapeutics.com PX’THERAPEUTICS, located in Grenoble (France), provides services in the field of recombinant protein development and GMP manufacturing. PX’THERAPEUTICS proposes custom programs targeting the development of monoclonal antibodies, humanization of therapeutic antibodies, protein engineering and optimization, feasibility studies, process development up to clinical and small-scale commercial batch production, in bacteria, yeasts or mammalian cells. Our subsidiary Promise Advanced Proteomics provides products and services in the field of quantitative proteomics. Date of creation: 2000 27 QuINTEN THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Diseases of the blood, immune disorders CONTACT: Alexandre TEMPLIER a.templier@quinten-france.com 11, rue Galvani 75017 PARIS Tel: +33(0)1 45 74 33 05 www.quinten.com QUINTEN is a strategy and operations consulting firm specialized in leveraging biomedical data for pharmaceutical, biotechnology and cosmetics companies. QUINTEN’s knowhow complements traditional modeling and data-mining techniques, since it enables to identify, characterize and enhance the value of sub-groups corresponding to best and worst practice in terms of patients’ response or resistance to a treatment, and occurrence of undesirable side-effects. Date of creation: 4/11/2008 Nombre d’employés: 15 SKuLDTECH SECTOR: • Diagnostic • R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system • Infectious and parasistic diseases • Cancer, oncology CONTACT: Didier RITTER info@skuldtech.com 1682, rue de la Valsière C.S. 77394 34184 MONTPELLIER Tel: +33 (0)4 67 41 97 48 www.skuldtech.com SKULDTECH aims to discover and validate new genomic and pharmacogenomic biomarkers for diagnostics and therapeutic purposes. Its approach is based on “Digital Gene Expression” method, New Generation Sequencing (NGS) technologies associated with its proprietary bionformatics and biostatistics tools. This expertise enables the Company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new therapeutics especially in cancer, rare diseases and infectious diseases. Date of creation: 14/06/1999 28 SYNCROSOME SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovasculr • Digestive system • Disease of nervous system CONTACT: Arnaud PEYRONNIER dvpt@syncrosome.com Case Postale 908 Luminy biotech entreprises 163, avenue de Luminy 13288 MARSEILLE Tel: +33 (0)4 95 05 31 80 www.syncrosome.com SYNCROSOME is focused on In Vivo Efficacy Studies dedicated to Discovery and Preclinical stage with more than 25 Animal Models, to provide you the right data to make the right decision. We offer our services and our expertise in the development of drugs in: GASTROENTEROLOGY, CENTRAL NERVOUS SYSTEM, CARDIOVASCULAR, RESPIRATORY, INFLAMMATION. We perform also Pharmacokinetics studies (multi-species). Concerning PK studies, we pay a special attention to CNS-PK to evaluate the in vivo BBB passage of your compounds. Date of creation: 2000 Nombre d’employés: 14 TExCELL SECTOR: R&D services/biotechnologies CONTACT: Bernard PLICHON info@texcell.com Bât. Genavenir 5 1, rue Pierre Fontaine 91058 EVRY Cedex Tel: +33 (0)1 60 91 33 10 www.texcell.com TEXCELL is a world-renowned company that provides Biosafety and immunology services in full compliance with GLP and GMP standards.Thanks to our in-depth experience of providing viral safety testing and virus validation studies, we have provided support to a large number products licensed by the FDA, the EMA and the MHW. TEXCELL is also your central lab for pre-clinical and clinical trials. We offer a dedicated technology platform in immunology. Based in France near Paris (Evry), TEXCELL has also a subsidiary in USA, with facilities in Middletown, MD., and soon in Frederick, specialized in no GMP Cell culture and GLP compliant viral clearance testing services. Date of creation: 1987 29 TROPHOS SECTOR: Therapeutics THERAPEuTIC AREA: • Cardiovasculr • Disease of nervous system CONTACT: Julien VEYS info@trophos.com Parc scientifique de Luminy Case 931 13288 MARSEILLE Tel: +33 (0)4 91 82 82 82 www.trophos.com TROPHOS is a late stage pharmaceutical company whose strategy is to create and realise value from its proprietary, innovative, cholesterol-oximes compound family of mitochondrial pore modulators by taking at least one program to clinical validation for orphan/niche indications in neurology and acute cardiology before an exit for investors. The Company has its lead product, olesoxime (TRO19622), in phase 2/3 development and TRO40303 in phase 2 development with funding secured up to the next step of value creation. Date of creation: 2000 VFP THERAPIES VFP Therapies Drugs: Highway to the Brain C : 100 - m : 47 - j : 0 -n : 40 SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system • Mmental & behavioural disorders • Cancer, oncology Typographie Century regular c : 100 -m : 10 -j : 0 -n : 10 CONTACT: Francis MARSAIS President and CEO contact@vfp-therapies.com 15, rue François Couperin 76000 ROUEN Mob.: +33 (0)6 80 32 57 64 www.vfp-therapies.com VFP THERAPIES is a young French company who has devised an innovative therapeutic approach aimed at treating brain diseases such as Alzheimer’s Disease by means of highly selective bioprecursor drugs. Such prodrugs do not deploy activity before they crossed the blood-brainbarrier, and hence do not induce significant side effects. Besides, one so can target receptor sites in the brain in a more selective way. The required amount of active principle as well as its toxicity can thereby be decreased. The core business of VFP THERAPIES is the development of proprietary drugs at the same time as joined development work on behalf of pharmaceutical and biotechnology companies. Date of creation: août 2012 Nombre d’employés: 6 30 notes .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. 31 notes .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. 32 notes .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. .................................................................................................................................................................. 33 BIO EUROPE 2O13 CONVENTION The French participation is organized by UBIFRANCE HEAD OFFICE IN PARIS 77, boulevard Saint-Jacques 75014 PARIS - FRANCE Tel: +33 (0)1 40 73 33 88 Fax: +33 (0)1 40 73 30 39 Jennifer OLSZOWY jennifer.olszowy@ubifrance.fr CONTACT IN AUSTRIA uBIFRANCE Vienna Reisnerstrasse 50/10 1030 VIENNE - AuTRICHE Tel: +43 (0)1 712 63 57 64 Mascha PAULIN mascha.paulin@ubifrance.fr WEBSITE www.ubifrance.com
